Herceptin combination treatment hailed
A new targeted breast cancer drug can increase the survival time of some hard-to-treat patients by almost six months, research has shown.
Get unlimited access
As a subscriber you will benefit from:
- Full online and mobile access to news and opinion stories
Customised email alerts straight to your inbox (over 30 alerts available)
- 4,500 practice articles in our archive
- Over £500 worth of CPD learning units